Generation and Characterization of Two Human a/f8 T cell Clones Recognizing Autologous Breast Tumor Cells through an HLA- and TCR/CD3-lndependent Pathway

Cell-mediated immune response to breast tumor has only been marginally investigated. To gain insight into this issue we have developed two clones of distinct phenotype, CD3 + a/fl, CD4+, CD8-, CD16-, and CD3+ a/l, CD4-, CD8+, CD16-, respectively, from peripheral blood lymphocytes (PBL) of a breast cancer patient. These effectors, selected on the basis of their cytolytic activity against autologous tumor cells and lack of lysis on NK-sensitive cell lines, preferentially recognize autologous tumor cells. The two clones' cytotoxic activity, while inhibited by anti-LFA-1 mAb, could not be abolished by mAbs to CD3, to class I and class II MHC molecules, and by mAbs to molecules involved in T cell function (i.e., CD4, CD8, CD2). The molecular of the a and P T cell receptor chains of the two cells, confirmed their clonality and showed that, despite an overlapping killing pattern, they possess distinct TCR a and ,f chains. findings demonstrate that breast tumor-specific CTL clones can be generated through current technology and that a a/p effector cell population operating through a HLA-un-restricted and TCR/CD3-independent pathway may be involved in the identification and killing of this tumor. (J. Clin. Invest. 1994. 94:1426-1431.)

[1]  A. Mantovani,et al.  T‐cell‐receptor engagement and tumor ICAM‐1 up‐regulation are required to by‐pass low susceptibility of melanoma cells to autologous CTL‐mediated lysis , 2009, International journal of cancer.

[2]  J. Bell,et al.  Characterization of the human T cell receptor α‐chain repertoire and demonstration of a genetic influence on Vα usage , 1993, European journal of immunology.

[3]  M. Herlyn,et al.  Melanoma cells and normal melanocytes share antigens recognized by HLA- A2-restricted cytotoxic T cell clones from melanoma patients , 1993, The Journal of experimental medicine.

[4]  F. Malavasi,et al.  Cell retargeting by bispecific monoclonal antibodies. Evidence of bypass of intratumor susceptibility to cell lysis in human melanoma. , 1992, The Journal of clinical investigation.

[5]  A. Lanzavecchia,et al.  Preferential V beta gene usage and lack of junctional sequence conservation among human T cell receptors specific for a tetanus toxin- derived peptide: evidence for a dominant role of a germline-encoded V region in antigen/major histocompatibility complex recognition , 1992, The Journal of experimental medicine.

[6]  R. Bast,et al.  Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. , 1991, Cancer research.

[7]  S. Roman-Roman,et al.  Studies on the human T cell receptor α/β variable region genes. II. Identification of four additional Vβ subfamilies , 1991 .

[8]  R. Freedman,et al.  Cytotoxic T cell clones isolated from ovarian tumor-infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells. , 1991, Journal of immunology.

[9]  H. Seigler,et al.  MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells. Evidence for restriction by a dominant HLA-A allele. , 1991, Journal of immunology.

[10]  M. Humphries,et al.  Human natural killer cells express VLA-4 and VLA-5, which mediate their adhesion to fibronectin. , 1991, Journal of immunology.

[11]  P. Fisher,et al.  Effect of recombinant human leukocyte, fibroblast, and immune interferons on expression of class I and II major histocompatibility complex and invariant chain in early passage human melanoma cells. , 1990, Cancer research.

[12]  Timothy A. Springer,et al.  Adhesion receptors of the immune system , 1990, Nature.

[13]  A. Anichini,et al.  Cellular immune response against autologous human malignant melanoma: are in vitro studies providing a framework for a more effective immunotherapy? , 1990, Journal of the National Cancer Institute.

[14]  R. Fauchet,et al.  Presence on a human melanoma of multiple antigens recognized by autologous CTL , 1989, International journal of cancer.

[15]  S. Rosenberg,et al.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.

[16]  M. Rinaldi,et al.  Use of selected combinations of monoclonal antibodies to tumor associated antigens in the diagnosis of neoplastic effusions of unknown origin. , 1988, European journal of cancer & clinical oncology.

[17]  A. Yagihashi,et al.  Characterization of n-butyl alcohol solubilized, breast tumor specific antigens recognized by a human autologous cytotoxic T-cell clone. , 1988, Cancer research.

[18]  M. Feldmann,et al.  Regulation of clonal growth by anti-T-cell receptor antibody-directed lysis. , 1988, Immunology.

[19]  S. Rosenberg,et al.  Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. , 1987, Journal of immunological methods.

[20]  J. C. Pratt,et al.  Direct evidence for the existence of nominal antigen binding sites on T cell surface Ti α-β heterodimers of MHC-restricted T cell clones , 1986, Cell.

[21]  R. Gambari,et al.  Human KJ29 cell line, isolated from a kidney adenocarcinoma: Morphological aspects and effects of chemical inducers , 1986 .

[22]  A. Anichini,et al.  Heterogeneity of clones from a human metastatic melanoma detected by autologous cytotoxic T lymphocyte clones , 1986, The Journal of experimental medicine.

[23]  T. Mak,et al.  Organization and sequences of the diversity, joining, and constant region genes of the human T-cell receptor beta chain. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[24]  E. Reinherz,et al.  Antigen recognition by human T lymphocytes is linked to surface expression of the T3 molecular complex , 1982, Cell.

[25]  R. Tosi,et al.  Human Ia molecules carrying DC1 determinants differ in both α- and β-subunits from Ia molecules carrying DR determinants , 1981 .

[26]  V. Quaranta,et al.  Serologic and immunochemical characterization of the specificity of four monoclonal antibodies to distinct antigenic determinants expressed on subpopulations of human Ia-like antigens. , 1981, Journal of immunology.

[27]  A. Anichini,et al.  T lymphocytes can mediate lysis of autologous melanoma cells by multiple mechanisms: Evidence with a single T cell clone , 2005, Cancer Immunology, Immunotherapy.

[28]  S. Rosenberg.  Immunotherapy of cancer using interleukin 2: current status and future prospects. , 1988, Immunology today.

[29]  L. Hood,et al.  Diversity and structure of human T-cell receptor beta-chain variable region genes. , 1986, Proceedings of the National Academy of Sciences of the United States of America.